S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?

Organon & Co. (OGN) Stock Price, News & Analysis

$18.45
+0.33 (+1.82%)
(As of 03/27/2024 ET)
Today's Range
$18.18
$18.50
50-Day Range
$15.50
$18.71
52-Week Range
$10.84
$24.79
Volume
1.65 million shs
Average Volume
2.09 million shs
Market Capitalization
$4.72 billion
P/E Ratio
4.61
Dividend Yield
6.07%
Price Target
$21.80

Organon & Co. MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
18.2% Upside
$21.80 Price Target
Short Interest
Healthy
3.97% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.37
Upright™ Environmental Score
News Sentiment
1.63mentions of Organon & Co. in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$49,939 Bought Last Quarter
Proj. Earnings Growth
2.94%
From $4.08 to $4.20 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.92 out of 5 stars

Medical Sector

23rd out of 939 stocks

Pharmaceutical Preparations Industry

10th out of 435 stocks

OGN stock logo

About Organon & Co. Stock (NYSE:OGN)

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

OGN Stock Price History

OGN Stock News Headlines

OGN Quantitative Stock Analysis
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Organon & Co (OGN)
Organon's Valuation Is Not Expensive
Organon Stock Is Still Worth A Look
Trending Stocks Sent To You In Real Time
Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar!
Organon & Co. (NYSE:OGN) Q4 2023 Earnings Call Transcript
Organon Stock (NYSE:OGN), Guidance and Forecast
Looking Into Organon's Recent Short Interest
Organon & Co (OGN) Fell on Missed Consensus
See More Headlines
Receive OGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organon & Co. and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Ex-Dividend for 3/14 Dividend
2/23/2024
Dividend Payable
3/14/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Fax
N/A
Employees
10,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.80
High Stock Price Target
$28.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+18.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$1.02 billion
Pretax Margin
10.75%

Debt

Sales & Book Value

Annual Sales
$6.26 billion
Cash Flow
$5.11 per share
Book Value
($0.27) per share

Miscellaneous

Free Float
252,647,000
Market Cap
$4.72 billion
Optionable
Not Optionable
Beta
0.81
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Kevin Ali (Age 64)
    CEO & Director
    Comp: $3.96M
  • Mr. Matthew M. Walsh (Age 57)
    Executive VP & CFO
    Comp: $1.84M
  • Ms. Susanne Gabriele Fiedler (Age 56)
    Executive VP & Chief Commercial Officer
    Comp: $1.44M
  • Mr. Joseph T. Morrissey Jr. (Age 59)
    Executive VP and Head of Manufacturing & Supply
    Comp: $1.54M
  • Ms. Rachel A. Stahler (Age 48)
    Executive VP & Chief Information Officer
  • Ms. Jennifer Halchak
    Vice President of Investor Relations
  • Mr. Kirke Weaver (Age 51)
    Executive VP, General Counsel & Corporate Secretary
  • Mr. Aaron Falcione (Age 53)
    Executive VP & Chief Human Resources Officer
  • Mr. Vittorio Nisita (Age 56)
    Executive VP & Head of Global Business Services
  • Ms. Meghan Rivera
    US Managing Director

OGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Organon & Co. stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organon & Co. in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" OGN shares.
View OGN analyst ratings
or view top-rated stocks.

What is Organon & Co.'s stock price target for 2024?

4 Wall Street analysts have issued 12-month price targets for Organon & Co.'s stock. Their OGN share price targets range from $18.00 to $28.00. On average, they anticipate the company's share price to reach $21.80 in the next twelve months. This suggests a possible upside of 18.2% from the stock's current price.
View analysts price targets for OGN
or view top-rated stocks among Wall Street analysts.

How have OGN shares performed in 2024?

Organon & Co.'s stock was trading at $14.42 on January 1st, 2024. Since then, OGN stock has increased by 27.9% and is now trading at $18.45.
View the best growth stocks for 2024 here
.

Are investors shorting Organon & Co.?

Organon & Co. saw a decrease in short interest during the month of February. As of February 29th, there was short interest totaling 9,710,000 shares, a decrease of 27.2% from the February 14th total of 13,340,000 shares. Based on an average daily volume of 3,630,000 shares, the short-interest ratio is presently 2.7 days. Approximately 3.8% of the shares of the stock are short sold.
View Organon & Co.'s Short Interest
.

When is Organon & Co.'s next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our OGN earnings forecast
.

How were Organon & Co.'s earnings last quarter?

Organon & Co. (NYSE:OGN) announced its quarterly earnings results on Thursday, February, 15th. The company reported $0.87 EPS for the quarter, beating analysts' consensus estimates of $0.73 by $0.14. The business had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.55 billion. Organon & Co. had a negative trailing twelve-month return on equity of 212.00% and a net margin of 16.33%.

How often does Organon & Co. pay dividends? What is the dividend yield for Organon & Co.?

Organon & Co. declared a quarterly dividend on Thursday, February 15th. Investors of record on Monday, February 26th will be paid a dividend of $0.28 per share on Thursday, March 14th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 6.07%. The ex-dividend date of this dividend is Friday, February 23rd.
Read our dividend analysis for OGN
.

Is Organon & Co. a good dividend stock?

Organon & Co. (NYSE:OGN) pays an annual dividend of $1.12 per share and currently has a dividend yield of 6.18%. OGN has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 28.00%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, OGN will have a dividend payout ratio of 26.67% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for OGN.

What guidance has Organon & Co. issued on next quarter's earnings?

Organon & Co. issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $6.2 billion-$6.5 billion, compared to the consensus revenue estimate of $6.4 billion.

Who are Organon & Co.'s major shareholders?

Organon & Co.'s stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.97%), Vanguard Group Inc. (11.97%), Massachusetts Financial Services Co. MA (3.99%), Sound Shore Management Inc. CT (1.83%), LSV Asset Management (1.31%) and Point72 Asset Management L.P. (1.25%). Insiders that own company stock include Kirke Weaver and Ma Fatima Francisco.
View institutional ownership trends
.

How do I buy shares of Organon & Co.?

Shares of OGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:OGN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners